Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction.
BACKGROUND
Abnormalities in the white matter of the brain may occur in individuals with schizophrenia as well as with normal aging. Therefore, elderly schizophrenic patients may suffer further cognitive decline as they age. This study determined whether elderly schizophrenia participants, especially those with declined cognitive function (Clinical Dementia Rating score > 1), show white matter metabolite abnormalities on proton magnetic resonance spectroscopy and whether there are group differences in age-dependent changes in these brain metabolites.


METHODS
Twenty-three elderly schizophrenia and twenty-two comparison participants fulfilling study criteria were enrolled. Localized, short echo-time (1)H MRS at 4 Tesla was used to assess neurometabolite concentrations in several white matter regions.


RESULTS
Compared with healthy subjects, schizophrenia participants had lower N-acetyl compounds (-12.6%, p = .0008), lower myo-inositol (-16.4%, p = .026), and higher glutamate + glutamine (+28.7%, p = .0016) concentrations across brain regions. Schizophrenia participants with Clinical Dementia Rating >/= 1 showed the lowest NA in the frontal and temporal regions compared with control subjects. Interactions between age and schizophrenia status on total creatine and choline-containing compounds were observed; only schizophrenia participants showed age-related decreases of these metabolites in the right frontal region.


CONCLUSIONS
Decreased NA in these white matter brain regions likely reflects reduced neuronal content associated with decreased synapses and neuronal cell volumes. The elevated glutamate + glutamine, if reflecting elevated glutamate, could result from excess neuronal glutamate release or glial dysfunction in glutamate reuptake. The decreased myo-inositol in participants with schizophrenia suggests decreased glial content or dysfunctional glia, which might result from glutamate-mediated toxicity.
Chang
Linda
L
Department of Medicine, John A. Burns School of Medicine, Honolulu, Hawaii 96813, USA. lchang@hawaii.edu
Friedman
Joseph
J
Ernst
Thomas
T
Zhong
Kai
K
Tsopelas
Nicholas D
ND
Davis
Kenneth
K
D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives / Q000378:metabolism; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D001931:Brain Mapping; D002794:Choline / Q000378:metabolism; D003401:Creatine / Q000378:metabolism; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009457:Neuroglia / Q000378:metabolism* / Q000473:pathology*; D011522:Protons; D012559:Schizophrenia / Q000473:pathology*
D011522:Protons; D005973:Glutamine; C010530:N-acetylalanine; D018698:Glutamic Acid; D003401:Creatine; D002794:Choline; D000409:Alanine
Arch Gen Psychiatry. 2005 Mar;62(3):254-62
15753238
Brain. 2005 May;128(Pt 5):1016-25
15758036
Am J Psychiatry. 2005 Mar;162(3):602-5
15741480
Am J Psychiatry. 2005 Jun;162(6):1206-8
15930072
Neuropsychopharmacology. 2005 Nov;30(11):1949-62
16123764
Biol Psychiatry. 2005 Nov 1;58(9):724-30
16018980
Glia. 2006 Jan 15;53(2):212-24
16206168
Neurology. 2006 Jan 24;66(2):217-22
16434657
Neuropsychopharmacology. 2006 Apr;31(4):751-6
16132064
Schizophr Res. 2006 Sep;86(1-3):1-14
16842972
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84
16773445
Int Rev Neurobiol. 2007;78:69-108
17349858
J Psychopharmacol. 2007 Jun;21(4):440-52
17259207
Schizophr Res. 2000 Feb 14;41(3):389-95
10728716
Schizophr Res. 2000 Aug 3;44(2):151-5
10913747
Neuron. 2000 Nov;28(2):547-58
11144363
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51
11296301
Magn Reson Med. 2001 May;45(5):899-907
11323817
Brain. 2001 May;124(Pt 5):882-92
11335691
Brain. 2001 May;124(Pt 5):953-61
11335697
Neuroreport. 2001 Jul 20;12(10):2251-4
11447344
Neurology. 2001 Aug 28;57(4):626-32
11524470
J Comp Neurol. 2002 Jan 14;442(3):277-91
11774342
Eur Arch Psychiatry Clin Neurosci. 2002 Jun;252(3):120-3
12192469
Schizophr Res. 2002 Oct 1;57(2-3):127-38
12223243
Biol Psychiatry. 2002 Nov 1;52(9):855-62
12399138
Am J Psychiatry. 2002 Nov;159(11):1944-6
12411236
Magn Reson Med. 2003 Mar;49(3):527-35
12594756
Am J Psychiatry. 2003 Mar;160(3):572-4
12611842
Arch Gen Psychiatry. 2003 May;60(5):443-56
12742865
Arch Gen Psychiatry. 2003 Aug;60(8):779-88
12912761
Am J Psychiatry. 2003 Dec;160(12):2231-3
14638596
Biol Psychiatry. 2004 Jan 15;55(2):126-30
14732591
Neuroimage. 2004 Jan;21(1):27-35
14741639
Schizophr Res. 2004 Apr 1;67(2-3):269-75
14984887
Magn Reson Med. 2004 Mar;51(3):435-40
15004781
Brain. 2004 Jun;127(Pt 6):1361-9
15128615
Biol Psychiatry. 2004 Sep 1;56(5):340-8
15336516
Arch Gen Psychiatry. 1986 Jan;43(1):36-42
2935114
Br J Psychiatry. 1987 Dec;151:744-52
3502800
Psychopharmacol Bull. 1988;24(4):637-9
3249765
Arch Gen Psychiatry. 1992 Aug;49(8):615-23
1637251
Magn Reson Med. 1993 Dec;30(6):672-9
8139448
JAMA. 1994 Dec 14;272(22):1763-9
7966925
Dev Neurosci. 1993;15(3-5):289-98
7805581
Magn Reson Med. 1995 Sep;34(3):308-12
7500867
Arch Gen Psychiatry. 1996 May;53(5):425-36
8624186
Life Sci. 1996;58(22):2049-56
8637436
Magn Reson Med. 1996 Sep;36(3):462-8
8875419
Neurology. 1997 Apr;48(4):836-45
9109865
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4757-60
9114064
Radiology. 1997 Jun;203(3):829-36
9169712
Acad Radiol. 1994 Nov;1(3):211-6
9419488
Arch Gen Psychiatry. 1998 Mar;55(3):215-24
9510215
Neuroreport. 1998 Feb 16;9(3):425-30
9512384
Neurology. 1999 Jan 1;52(1):100-8
9921855
Magn Reson Med. 1999 Feb;41(2):276-84
10080274
Arch Gen Psychiatry. 1999 Apr;56(4):367-74
10197834
Am J Psychiatry. 1999 Aug;156(8):1200-4
10450260
Neuropsychobiology. 2004;50(4):296-300
15539860
Alcohol Clin Exp Res. 2004 Dec;28(12):1849-60
15608601